

 **OLIGOS &
PEPTIDES**
WORLD ASIA 2027

Advancing Oligonucleotide & Peptide Therapeutics from Clinical R&D to Manufacturing in Asia

 23 - 24 March 2027 Sands Expo & Convention Centre, Singapore

PART OF



**BIOPHARMA APAC
CONFEX**
BIOPHARMA ASIA PACIFIC
CONFERENCE, EXHIBITION
& AWARDS

MANUFACTURING | ADC | CDT | CLINICAL TRIALS | TIDES | SUPPLY CHAIN

OFFICIAL EVENT BROCHURE

<https://infohub.imapac.com/opwa-2027>

Table of Contents

About the Event	3
Sponsors & Media Partners	4
2027 Speakers	5
Agenda At A Glance	6
Agenda	7
Expected Audience Snapshot	15
Who Should Sponsor?	16
Why Sponsor This Event?	16
Our Past Partners	17
Add to Calendar	18
Registration Form	19
About IMAPAC	21

EVENT CONTACTS

CONFERENCE PRODUCER

Dee Calucin
diann.calucin@imapac.com
+6562303595

HEAD OF PRODUCTION

Lara Santiago
lara.santiago@imapac.com
+639176210686

BUSINESS DEVELOPMENT MANAGER

Ana Laxamana
ana.laxamana@imapac.com
+6569836132

SENIOR NETWORKING DELEGATE EXECUTIVE

Niti Gupta
niti.gupta@imapac.com
+6569901633

Nathan Grace Niño
nathan.grace@imapac.com
+6569836134

EVENT HIGHLIGHTS

300+
ATTENDEES

120+
COMPANIES

35+
SPEAKERS

DATE & VENUE

23 - 24 March 2027

Sands Expo & Convention Centre
Singapore

CO-LOCATED EVENTS



About the Event

Oligos & Peptides World Asia 2027 is the region's leading platform dedicated to advancing oligonucleotide and peptide-based therapeutics across the value chain — from early-stage R&D and clinical trials to large-scale manufacturing.

As Asia emerges as a key hub for next-generation therapeutics, the event will bring together leaders from biopharma and big pharma, alongside regulatory experts, to exchange insights, explore innovation, and strengthen regional collaboration. Through a carefully curated programme featuring case studies from across APAC, the programme aims to accelerate development pipelines and drive manufacturing excellence in oligonucleotide and peptide therapies.

Spanning eight focused sessions, Oligos & Peptides World Asia 2027 will explore the latest advancements in ASOs, siRNA, and peptide therapeutics; innovative delivery and formulation technologies; and progress in clinical trials and translational research across the region. The programme will also address scalable manufacturing, evolving regulatory frameworks, emerging digital and platform innovations, and best practices in quality and analytical strategies — offering a comprehensive view of Asia's expanding oligonucleotide and peptide ecosystem, from R&D to large-scale production.

Sponsors & Media Partners

EXHIBITOR



Honya Biotech

MEDIA & PUBLICITY



Life Sciences
Review



Open access content covering oligonucleotides, mRNA, DNA, delivery, and more

Head of Production:

Lara Santiago · lara.santiago@imapac.com · +639176210686

Business Development Manager:

Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

2027 SPEAKERS



Andy Xian Zheng, PhD

CEO

Byterna Therapeutics

 SINGAPORE



Alap Gandhi

Country Medical Director

GSK

 MALAYSIA



Bin Xia Yang

Director

Hengrui R&D Centre

 SINGAPORE



Prof. Rakesh Veedu

Professor/Co-Founder & MD/CEO

**Murdoch University/ ProGenis
Pharmaceuticals**

 AUSTRALIA



Wonil Kim

CSO

Aston Sci

 SOUTH KOREA



Dr. Pratik Dave

Senior Scientist

Roche

 SWITZERLAND



**Dr. Bharti Prafulla
Deshmukh**

HOD of RND Peptide Genric

Hovid Bhd

 MALAYSIA



Stephen Lin

Vice General Manager

ExoOne Bio

 TAIWAN

Agenda At A Glance

CONFERENCE DAY 1 23RD MARCH 2027, WEDNESDAY	CONFERENCE DAY 2 24TH MARCH 2027, THURSDAY
Asia's Frontier in Oligonucleotide Therapeutic	From Asia to Global Clinical Development & Regulatory Approval
MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING	
Peptide Therapeutics 2.0 Beyond GLP-1	Oligonucleotide Manufacturing From Synthesis to Commercial Scale
LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING	
Breaking the Delivery Barrier From Oral Peptides to Precision Oligos	Peptide Manufacturing Scale, Cost & GMP Readiness
AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING	
Convergence Peptide - Oligonucleotide Conjugates & Hybrid Modalities	Closing Roundtable Discussion Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia Biologics Manufacturing Asia - Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality? - Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia? - CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance? ADC Asia Congress - Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results? - From Bench to Bedside: What's Missing in Translating Preclinical ADC Wins to Clinical Success? - Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities BioSupply Chain Asia - Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today? - Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains? - Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations? Clinical Trials Festival Asia - Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia? - Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research? Oligos & Peptides World Asia - Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges - Beyond Purity: Managing Peptide Aggregation, Degradation & Stability
END OF CONFERENCE DAY 1	END OF CONFERENCE
ASIA PACIFIC BIOPHARMA EXCELLENCE AWARDS 2027 GALA DINNER	

Day 1

Tuesday, 23 March 2027

8:50

IMAPAC's Opening Remarks

8:55

Chairman's Welcome Address

Asia's Frontier in Oligonucleotide Therapeutics

9:00

Leadership Panel: From Manufacturing Powerhouse to Innovation Leader — Can Asia Lead the Next Generation of Oligonucleotide Therapeutics?

- Positioning APAC as a global hub for oligonucleotide discovery, development and commercialization
- Building stronger links between biotech innovation, pharma, academia, CDMOs and investors
- Moving Asia beyond manufacturing toward globally originated therapeutic pipelines
- Identifying the capabilities and partnerships required to compete globally



Bin Xia Yang

Director, Hengrui R&D Centre

9:50

Engineering the Next Generation of ASO & siRNA Therapeutics: Potency, Precision & Durability

- Advancing ASO and siRNA design for improved potency and selectivity
- Optimising chemical modifications to enhance stability and therapeutic performance
- Balancing efficacy, safety, durability and dosing frequency
- Accelerating candidate selection from discovery into clinical development



Reserved for Solution Provider

10:05

Beyond the Liver: Breaking the Extrahepatic Delivery Barrier for Oligonucleotide Therapeutics

- Expanding delivery beyond hepatic targets into CNS, muscle, immune cells and other tissues
- Advancing receptor- and ligand-mediated targeting approaches
- Overcoming endosomal escape and intracellular delivery barriers
- Translating promising delivery technologies from preclinical models into patients

10:30

Morning Tea, Exhibition Viewing & 1-1 Networking

Peptide Therapeutics 2.0 — Beyond GLP-1

11:15

Beyond GLP-1: Where Will the Next Generation of Peptide Blockbusters Come From?

- Expanding peptide therapeutics into oncology, immunology, CNS and rare diseases
- Identifying opportunities beyond metabolic and obesity indications
- Advancing multi-agonist, multispecific and multifunctional peptide platforms
- Differentiating peptides from antibodies and small molecules

11:40

Cyclic & Constrained Peptides: Unlocking Intracellular and Previously Undruggable Targets

- Using cyclic and constrained architectures to improve affinity and selectivity
- Accessing intracellular targets traditionally considered undruggable
- Improving proteolytic stability, permeability and pharmacokinetics
- Translating complex peptide scaffolds into developable drug candidates



Reserved for Solution Provider

11:55

Engineering Long-Acting Peptides: Extending Half-Life Without Compromising Potency & Safety

- Designing peptides for extended systemic exposure and reduced dosing frequency
- Evaluating lipidation, conjugation, depot and sustained-release strategies
- Balancing half-life extension with potency, stability and safety
- Developing more convenient and patient-friendly dosing strategies

12:20

Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking

Breaking the Delivery Barrier — From Oral Peptides to Precision Oligos

2:05

Panel Discussion: Oral Peptide Delivery: Can We Finally Break the Bioavailability Barrier

- Overcoming enzymatic degradation and gastrointestinal barriers
- Evaluating permeation enhancers and novel formulation technologies
- Improving oral bioavailability while maintaining safety
- Translating promising oral peptide technologies into commercially viable therapies

2:35

Precision Peptide Delivery: Engineering Tissue-Specific & Intracellular

- Engineering peptides to overcome membrane and physiological barriers
- Advancing receptor-mediated and ligand-directed tissue targeting
- Optimising biodistribution while reducing off-target exposure
- Translating preclinical delivery performance into clinically meaningful exposure



Reserved for Solution Provider

2:50

Next-Generation Delivery Platforms for RNA & Oligonucleotide Therapeutics

- Comparing emerging delivery technologies beyond conventional approaches
- Exploring extracellular vesicles and other next-generation carriers
- Improving cargo loading, cellular uptake and tissue specificity
- Addressing scalability, manufacturability and clinical translation



Stephen Lin

Vice General Manager, ExoOne Bio

3:25

Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Networking

Convergence — Peptide–Oligonucleotide Conjugates & Hybrid Modalities

4:10

Beyond GalNAc: Peptide–Oligonucleotide Conjugates for the Next Frontier of Targeted

- Identifying where peptide-enabled targeting can outperform existing delivery technologies
- Expanding oligonucleotide delivery into difficult tissues and cell types
- Comparing cell-penetrating, receptor-targeting and tissue-specific peptides
- Determining which conjugate platforms offer the strongest clinical and commercial potential

4:35

Conjugate by Design: Engineering Peptide–Linker–Oligonucleotide Architectures for Maximum Therapeutic Performance

- Optimising peptide, linker and oligonucleotide architecture
- Balancing potency, selectivity, stability, PK/PD and intracellular release
- Selecting conjugation strategies based on target tissue and mechanism
- Using computational and AI-enabled approaches to accelerate candidate optimisation



Reserved for Solution Provider

4:55

From Chemistry to Clinic: Scaling Peptide–Oligonucleotide Conjugates for Commercial Manufacturing

- Scaling synthesis and conjugation while maintaining yield and purity
- Controlling conjugation-related heterogeneity and critical quality attributes
- Overcoming purification challenges for increasingly complex molecules
- Building scalable CMC strategies from clinical development to commercial supply

5:20

Chairman's Closing Remarks

5:30

END OF DAY 1 CONFERENCE

6:00

COCKTAILS & NETWORKING

6:30

ASIA-PACIFIC BIOPHARMA EXCELLENCE AWARDS 2027 GALA DINNER

Day 2

Wednesday, 24th March 2027

8:50

IMAPAC's Opening Remarks

8:55

Chairman's Welcome Address

From Asia to Global Clinical Development & Regulatory Approval

9:00

Oligos:

From Asia to Global Approval: Navigating Regulatory & CMC Pathways for Oligonucleotide Therapeutics

- Addressing oligonucleotide-specific regulatory and CMC expectations
- Managing sequence-related impurities, chemical modifications and comparability
- Aligning development strategies across the US, Europe, China, Japan, Korea and Singapore
- Designing APAC programmes capable of supporting global regulatory submissions

9:25

From First-in-Human to Global Development: De-Risking Clinical Translation from Asia

- Translating preclinical PK/PD, biodistribution and toxicology into clinical dose selection
- Designing efficient first-in-human and early-phase trials
- Selecting biomarkers and endpoints to demonstrate proof of mechanism
- Using APAC clinical development to accelerate progression into global programmes



Reserved for Solution Provider

9:40

Peptides:

From Asia to Global Approval: Regulatory & CMC Strategies for Next-Generation Peptide Therapeutics

- Addressing regulatory requirements for conventional, cyclic, modified and complex peptides
- Establishing specifications around purity, degradation, stability and product quality
- Managing manufacturing changes and comparability throughout development
- Building regulatory strategies that enable Asia-developed therapies to enter global markets

10:05

From Accelerated Approval to Global Launch: Late-Stage Development & Lifecycle Strategy for Oligos and Peptides

- Translating clinical evidence into patient access
- Building evidence strategies for innovative therapeutics
- Navigating regulatory and healthcare stakeholder requirements
- Moving therapies from development toward real-world adoption



Alap Gandhi

Country Medical Director, GSK

10:30

Morning Break, Exhibition Viewing & 1-1 Networking

Oligonucleotide Manufacturing — From Synthesis to Commercial Scale

11:15

From Clinical Supply to Commercial Manufacturing: Building Scalable Oligonucleotide Processes

- Moving from development-scale synthesis into robust GMP manufacturing
- Establishing scalable processes for increasing commercial demand
- Managing technology transfer between internal facilities and CDMOs
- Building supply strategies that support clinical and commercial growth

11:40

Scaling Oligonucleotide Synthesis: Yield, Purity, Solvent Reduction & Commercial Throughput

- Improving coupling efficiency, cycle times and overall synthesis yield
- Reducing solvent and reagent consumption at commercial scale
- Managing sequence length and complexity as pipelines evolve
- Increasing throughput without compromising product quality



Reserved for Solution Provider

11:55

Greener & Smarter Oligo Manufacturing: Can New Technologies Transform the Economics of Synthesis?

- Reducing solvent intensity, waste and environmental footprint
- Evaluating alternative and hybrid synthesis technologies
- Applying automation, digitalisation and process monitoring
- Balancing sustainability improvements with COGS and manufacturing performance

12:20

Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking

Peptide Manufacturing — Scale, Cost & GMP Readiness

2:05

Scaling Peptide Therapeutics for Commercial Manufacturing: From Solid-Phase Synthesis to GMP & Regulatory Readiness

- Developing robust peptide processes from bench scale to cGMP manufacturing
- Managing process optimisation, scale-up and manufacturing transfer
- Integrating analytical method development with peptide process development
- Preparing peptide products for regulatory and DMF requirements across the US and Europe



Dr. Bharti Prafulla Deshmukh

HOD of RND Peptide Genric, Hovid Bhd

2:30

Reducing the Cost of Peptide Manufacturing at Commercial Scale: SPPS, LPPS & Process Intensification

- Reducing resin, solvent and reagent consumption
- Comparing SPPS, LPPS and hybrid manufacturing approaches
- Improving coupling efficiency, yield and throughput
- Identifying opportunities to significantly reduce commercial COGS



Reserved for Solution Provider

2:45

Purification: The Hidden Bottleneck in Commercial Peptide Manufacturing

- Tackling purification challenges as peptide complexity increases
- Improving recovery and purity without sacrificing manufacturing yield
- Optimising chromatography and alternative purification strategies
- Reducing purification time, solvent consumption and cost at commercial scale

3:10

From Bench to GMP: Scaling Complex Peptide Therapeutics Without Losing Quality

- Translating laboratory processes into robust GMP manufacturing
- Establishing CQAs and process controls during scale-up
- Managing technology transfer and manufacturing comparability
- Integrating analytical development with peptide process development

3:35

Afternoon Tea, Exhibition Viewing & 1-1 Networking

Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia

4:20

Biologics Manufacturing Asia

- Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
- Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
- CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?

ADC Asia Congress

- Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
- From Bench to Bedside: What's Missing in Translating Preclinical ADC Wins to Clinical Success?
- Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities

BioSupply Chain Asia

- Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
- Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
- Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?

Clinical Trial Asia

- Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
- Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?

Oligos & Peptides Asia

- Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
- Beyond Purity: Managing Peptide Aggregation, Degradation & Stability

5:20

Chairman's Closing Remarks

5:30

END OF DAY 2 CONFERENCE

Expected Audience Snapshot

80%


ATTENDANCE FROM APAC REGION

75%


DECISION MAKERS

BY PROFILE


Oligonucleotide & Peptide Therapeutics Developers (Asia) **35%**




Oligonucleotide & Peptide Therapeutics Developers (International) **15%**




Big Pharma & Biopharmaceutical Companies **15%**




CROs, CMOs & CDMOs **15%**




Government, Academic & Research Institutes **8%**



Technology, Equipment & Service Providers **10%**




Others **2%**




BY JOB TITLE


CEOs, CSOs, CTOs, Presidents & C-Suite Executives **15%**




VPs, Directors & Heads of Oligonucleotide & Peptide Development, Manufacturing & CMC **30%**




Heads & Managers of Process Development, Analytical Development, Quality & Regulatory Affairs **25%**




Research Scientists, Principal Scientists & Professors **15%**



Business Development, Commercial & Strategic Partnerships **10%**



Others **5%**



BY GEOGRAPHY

20%

Europe, USA & Rest of World

25%

China & Taiwan

20%

Japan & South Korea

15%

Australia & India

20%

Hong Kong & South East Asia

Who Should Sponsor?

Oligonucleotide & Peptide CDMOs

Synthesis Equipment & Technology Providers

Analytical & Characterization Technology Providers

Purification & Chromatography Providers

Raw Materials & Reagent Suppliers

Solid-Phase Synthesis Equipment & Automation

Quality Control, Testing & Characterization Services

Contract Research Organizations (CROs)

Drug Delivery Systems & Formulation Technologies

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Our Past Partners



Head of Production:

Lara Santiago · lara.santiago@imapac.com · +639176210686

Business Development Manager:

Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

MARK YOUR CALENDAR

Save the Date

23 - 24 **MAR**
2027 Sands Expo & Convention Centre

Oligos & Peptides World Asia 2027

ALL IMAPAC EVENTS



Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific: biopharmaceutical conferences, summits and exhibitions for the year ahead.



OR ADD THIS EVENT TO YOUR CALENDAR

**Google Calendar**

One-click add to Gmail

**Outlook Calendar**

Add to Microsoft Outlook

**Scan to Register**

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

CATEGORY	EARLY BIRD (By 3 Oct 2026)	REGISTRATION (By 5 Dec 2026)	STANDARD (By 6 Feb 2027)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595
BRING YOUR TEAM - Group Discount				
Asia & International Biopharma ☐ Buy 2, Get 3 passes ☐ Buy 3, Get 5 passes Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes. INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount. - Access to all conference proceedings for up to 30 days. - Site Tour Package is applicable only with the purchase of a conference pass.				
Standard Package Group Discount				
3 Delegates Save 10% 5 Delegates Save 20% 6+ Delegates Save 25%				

EVENT VENUE



Sands Expo & Convention Centre
Singapore
23 - 24 March 2027

3 EASY WAYS TO REGISTER

Online
Visit:
<https://www.imapac.com/events/oligonucleotides-peptides-world-asia-congress-2027#register>

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name

Job Title

Address

Postcode

Tel

Email

Your primary business

Authorising Manager

Organization

Country

Fax

Authorising manager signature

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay:
☐ Credit Card
☐ Bank Transfer
☐ Cheque

Offline credit card:
☐ Visa
☐ MasterCard
☐ American Express

Online credit card payment: Please register at <https://www.imapac.com/events/oligonucleotides-peptides-world-asia-congress-2027#register>

Name on Card

Card Number

Expiry Date (MM/YY)

CVC Code

Signature

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received. Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers). Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.



**BIOPHARMA APAC
CONFEX** BIOPHARMA ASIA PACIFIC
CONFERENCE, EXHIBITION
& AWARDS

MANUFACTURING

ADC

CGT

CLINICAL TRIALS

TIDES

SUPPLY CHAIN

THIS EVENT IS PART OF

Biopharma APAC Confex 2027

Multiple Modalities. Decision-Makers Only.

Biopharma APAC Confex is Asia-Pacific's leading biopharma gathering, bringing together 2,000+ attendees and 700+ companies across co-located conferences spanning biologics manufacturing, clinical trials, ADCs, cell & gene therapy, TIDES, and supply chain innovation — supporting collaboration, knowledge sharing, and strategic partnerships across the region.

2000+

ATTENDEES

700+

COMPANIES

250+

SPEAKERS

72+

NETWORKING HOURS

CO-LOCATED CONFERENCES

**ADC ASIA
CONGRESS 2027**

**BIOLOGICS
MANUFACTURING ASIA 2027**

**BIOSUPPLY
CHAIN ASIA 2027**

**CLINICAL TRIALS
FESTIVAL ASIA 2027**

**CELL & GENE
THERAPY WORLD
ASIA 2027**

**OLIGOS &
PEPTIDES
WORLD ASIA 2027**



23–24 March 2027

Sands Expo & Convention Centre, Singapore

biopharmaapacconfex.com

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[Learn More →](#)



HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the

core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE

imapac.com

EMAIL

info@imapac.com

IMAPAC PTE LTD

36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD

77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN

@imapac

X

@imapac

FACEBOOK

ImapacPteLtd